CD8A and neoplasm: Using human SU-DHL4 cells as DLBCL tumor cell targets, we co-cultured activated CD8+ CTLs with or without PBMC-derived Tregs from patients and healthy donors at effector: target ratios of 5:1,10:1and 20:1.